Overview of systematic reviews/Meta-analysis of Xingnaojing Injection in treatment of cerebral ischaemic stroke.
10.19540/j.cnki.cjcmm.20210326.503
- Author:
Ye-Fei WANG
1
;
Zhen-Min XU
2
;
Shao-Jiao LIU
2
;
Ling-Ling DAI
2
;
Chun-Yan GUO
2
;
Liu-Ding WANG
3
;
Wen-Ran QIU
3
;
Xiao LIANG
3
;
Ming-Hua WU
4
;
Xiang-Lan JIN
5
;
Xing LIAO
6
Author Information
1. Dongfang Hospital, Beijing University of Chinese Medicine Beijing 100078, China Center for Evidence-based Chinese Medicine, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
2. Graduate School, Beijing University of Chinese Medicine Beijing 100029, China.
3. Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
4. Encephalopathy Center, Jiangsu Hospital of Traditional Chinese Medicine Nanjing 210029, China.
5. Dongfang Hospital, Beijing University of Chinese Medicine Beijing 100078, China.
6. Center for Evidence-based Chinese Medicine, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
- Publication Type:Meta-Analysis
- Keywords:
AMSTAR-2;
GRADE;
Xingnaojing Injection;
cerebral ischaemic stroke;
overview of systematic reviews
- MeSH:
Brain Ischemia/drug therapy*;
Drugs, Chinese Herbal;
Humans;
Ischemic Stroke;
Stroke/drug therapy*;
Systematic Reviews as Topic
- From:
China Journal of Chinese Materia Medica
2021;46(12):2972-2983
- CountryChina
- Language:Chinese
-
Abstract:
There have been many clinical trials, systematic reviews/Meta-analysis proving that Xingnaojing Injection has a good clinical efficacy in treatment of cerebral ischaemic stroke, but with fewer comprehensive descriptions. In this study, an overview of systematic reviews/Meta-analysis of Xingnaojing Injection in treating cerebral ischaemic stroke was performed to provide current situation of evidences and basis for clinical practice. CNKI, Wanfang, VIP, CBM, EMbase, PubMed, Cochrane Library, Web of Science were retrieved through computers. A total of 6 literatures were included in this study. By AMSTAR-2 checklist and GRADE, the quality of included systematic reviews and the efficacy of Xingnaojing Injection were evaluated. The results of AMSTAR-2 checklist showed an extremely low quality for all of the 6 systematic reviews. According to the results of GRADE evaluation, among 55 outcomes, there were 2 outcomes with a medium quality, 4 outcomes with a low quality and 49 outcomes with an extremely low quality. The 6 systematic reviews reached a consistent conclusion that Xingnaojing Injection was effective in the treatment of cerebral ischaemic stroke. This therapy could improve the total efficacy, neurological deficit scores, hemodynamic and hemodynamic parameters. However, the methodolo-gical quality of all literatures was extremely low. The evidence levels of outcomes were between extremely low to medium. The effectiveness of Xingnaojing Injection in the treatment of cerebral ischaemic stroke still needs to be further verified by more high-quality studies. In the future, relevant clinical studies and systematic reviews/Meta-analysis shall be carried out in a strict accordance with relevant regulations.
